Sinogene nets tens of millions of yuan in Series B1 round

Sinogene recently announced that it has completed tens of millions of yuan in Series B1 round of financing led by Shunqi Fund.

Sinogene recently announced that it has completed tens of millions of yuan in Series B1 round of financing led by Shunqi Fund.

Proceeds from this round of financing will be mainly used for the company’s long-term development of industrialization strategy layout, thorough development of the pet market, model animal achievement transformation and industrial applications.

Sinogene focuses on animal gene technology and technological innovation. From gene testing, gene editing, cell therapy to animal cloning, the company has achieved close-loop management of animal life cycle.

It is the first commercial pet cloning company in China with completely independent intellectual property rights.

Relying on canine cell cloning technology, Sinogene cooperates with more than 600 high-quality pet hospitals across the country to establish Sinogene Pet Cloning Designated Hospital to market dog cloning, cell preservation, genetic testing and other businesses.

Disclaimer: This is an article created by Michael Liang for Chinasdg.org. You can find the original article here: https://chinasdg.org/2020/06/25/sinogene-nets-tens-of-millions-of-yuan-in-series-b1-round/.

Leave a Reply

Please Login to Comment